EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

· Welcome to another exciting episode of Eye Care insider :13

· Intro Nancy Lurker :22

· Lurker’s background :58

· EyePoint Pharmaceuticals: the origin and transition 2:29

· Yutiq and long-acting drug delivery systems 6:07

· Additional indications for Yutiq 8:30

· What is the key factor in delivering this longer durability? 16:13

· Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47

· Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19

· Investor information and neural protection data 29:01

· What is the most important issue that the field of ophthalmology is currently facing? 30:38

· Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.